title: The Case for Adjunctive Monoclonal Antibody Immunotherapy in Schizophrenia.
abstract: This article presents the case in favor of clinical trials of adjunctive monoclonal antibody immunotherapy in schizophrenia. Evidence for prenatal and premorbid immune risk factors for the development of schizophrenia in the offspring is highlighted. Then key evidence for immune dysfunction in patients with schizophrenia is considered. Next, previous trials of adjunctive anti-inflammatory or other immunotherapy in schizophrenia are discussed. Then evidence for psychosis as a side effect of immunotherapy for other disorders is discussed. Also presented is preliminary evidence for adjunctive monoclonal antibody immunotherapy in psychiatric disorders. Finally, important considerations in the design and implementation of clinical trials of adjunctive monoclonal antibody immunotherapy in schizophrenia are discussed.
authors.affiliation: Department of Psychiatry and Health Behavior, Augusta University, 997 Saint Sebastian Way, Augusta, GA 30912, USA. Electronic address: brmiller@gru.edu.
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Miller
authors.affiliation: Medical College of Georgia, Augusta University, 1120 15th Street, AA-1006, Augusta, GA 30912, USA.
authors.forename: Peter F
authors.initials: PF
authors.lastname: Buckley
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D006801:Humans; D007154:Immune System Diseases / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D007167:Immunotherapy / Q000379:methods; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal
keywords: Adjunct; Cytokine; Immune; Inflammation; Monoclonal antibody; Psychosis; Schizophrenia; Treatment